[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1734 Reported in House (RH)]

<DOC>





                                                  Union Calendar No. 34
118th CONGRESS
  1st Session
                                H. R. 1734

                          [Report No. 118-50]

 To require coordinated National Institute of Standards and Technology 
  science and research activities regarding illicit drugs containing 
xylazine, novel synthetic opioids, and other substances of concern, and 
                          for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             March 23, 2023

  Mr. Collins (for himself, Ms. Caraveo, Mr. Lucas, Ms. Lofgren, Mr. 
Crawford, Mrs. Foushee, Mr. Obernolte, Mrs. McClellan, Mr. Kean of New 
   Jersey, Ms. Ross, Mr. Mike Garcia of California, Mr. Mullin, Ms. 
Tenney, Mr. Sorensen, Mr. Williams of New York, Mr. Trone, Mr. Weber of 
Texas, Mr. Babin, and Mr. Strong) introduced the following bill; which 
    was referred to the Committee on Science, Space, and Technology

                              May 5, 2023

 Additional sponsors: Mr. C. Scott Franklin of Florida, Mr. Miller of 
 Ohio, Mr. Jackson of North Carolina, Ms. Stevens, Mrs. Sykes, Ms. Lee 
                    of Pennsylvania, and Mr. Pappas

                              May 5, 2023

  Reported with an amendment, committed to the Committee of the Whole 
       House on the State of the Union, and ordered to be printed


_______________________________________________________________________

                                 A BILL


 
 To require coordinated National Institute of Standards and Technology 
  science and research activities regarding illicit drugs containing 
xylazine, novel synthetic opioids, and other substances of concern, and 
                          for other purposes.


 


    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Testing, Rapid Analysis, and 
Narcotic Quality Research Act'' or the ``TRANQ Research Act''.

SEC. 2. XYLAZINE DETECTION AND ANALYSIS.

    (a) In General.--The Director shall--
            (1) support NIST intramural basic measurement science and 
        research to advance--
                    (A) analytical methods to identify, understand, 
                differentiate, and categorize illicit drugs containing 
                xylazine, novel synthetic opioids, or other emerging 
                substances of concern;
                    (B) measurement technologies to shorten analysis 
                timelines and enhance narcotic and opioid detection and 
                analysis capabilities in illicit drugs;
                    (C) new data tools, techniques, and processes to 
                identify and publicly disclose relevant information 
                concerning illicit drugs containing xylazine, novel 
                synthetic opioids, or other emerging substances of 
                concern; and
                    (D) all other areas determined by the Director to 
                be critical to the development and deployment of 
                technologies to measure and analyze the presence of 
                xylazine, novel synthetic opioids, and other emerging 
                substances of concern in illicit drugs;
            (2) support activities to inform and expand the development 
        of near-real time spectrometry capabilities regarding xylazine, 
        novel synthetic opioids, and other emerging compounds in 
        illicit drugs;
            (3) convene the private sector, institutions of higher 
        education, nonprofit organizations, Federal laboratories, and 
        other Federal agencies engaged in the analysis of illicit drugs 
        to develop coordinated strategies and voluntary best practices 
        for the safe handling, transport, and analysis of illicit drugs 
        containing xylazine, novel synthetic opioids, or other emerging 
        substances of concern;
            (4) establish or expand collaborative partnerships or 
        consortia with other government agencies engaged in 
        counternarcotic research and development, institutions of 
        higher education, Federal laboratories, and the private sector 
        to enhance narcotic and opioid detection and analysis 
        capabilities regarding xylazine, novel synthetic opioids, and 
        other emerging substances of concern in illicit drugs; and
            (5) provide opportunities for graduate and postgraduate 
        research on the detection and identification of xylazine, novel 
        synthetic opioids, and other emerging substances of concern in 
        illicit drugs.
    (b) Controls.--In carrying out activities authorized under this 
section, the Director shall ensure proper security controls are 
implemented to protect sensitive information, as appropriate.
    (c) Definitions.--In this section:
            (1) Director.--The term ``Director'' means the Director of 
        the National Institute of Standards and Technology.
            (2) Federal laboratory.--The term ``Federal laboratory'' 
        has the meaning given such term in section 4 of the Stevenson-
        Wydler Technology Innovation Act of 1980 (15 U.S.C. 3703).
            (3) Institution of higher education.--The term 
        ``institution of higher education'' has the meaning given such 
        term in section 101 of the Higher Education Act of 1965 (19 
        U.S.C. 1001).
            (4) NIST.--The term ``NIST'' means the National Institute 
        of Standards and Technology.
            (5) Nonprofit organization.--The term ``nonprofit 
        organization'' means an organization described in section 
        501(c)(3) of the Internal Revenue Code of 1986 and exempt from 
        tax under section 501(a) of such code.
            (6) Xylazine.--The term ``xylazine'' means the nonopioid 
        tranquilizer methyl benzene compound frequently used in 
        veterinary medicine as an emetic and sedative with analgesic 
        and muscle relaxant properties.

SEC. 3. REPORT.

    Not later that 1 year after the date of enactment of this Act, the 
Director of the National Institute of Standards and Technology shall 
submit to the Committee on Science, Space, and Technology of the House 
of Representatives and the Committee on Commerce, Science, and 
Transportation of the Senate a report on the implementation of this 
Act. Such report may include legislative recommendations to improve the 
Director's ability to carry out section 2.
                                                  Union Calendar No. 34

118th CONGRESS

  1st Session

                               H. R. 1734

                          [Report No. 118-50]

_______________________________________________________________________

                                 A BILL

 To require coordinated National Institute of Standards and Technology 
  science and research activities regarding illicit drugs containing 
xylazine, novel synthetic opioids, and other substances of concern, and 
                          for other purposes.

_______________________________________________________________________

                              May 5, 2023

  Reported with an amendment, committed to the Committee of the Whole 
       House on the State of the Union, and ordered to be printed